Overcoming resistance of cancer cells to apoptosis

被引:104
作者
Hersey, P [1 ]
Zhang, XD [1 ]
机构
[1] Newcastle Mater Misericordiae Hosp, Immunol & Oncol Unit, Newcastle, NSW, Australia
关键词
D O I
10.1002/jcp.10256
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Discovery of the B cell lymphoma gene 2 (Bcl-2 gene) led to the concept that development of cancers required the simultaneous acquisition, not only of deregulated cell division, but also of resistance to programmed cell death or apoptosis. Apoptosis is arguably the common pathway to cell death resulting from a range of therapeutic initiatives, so that understanding the basis for the resistance of cancer cells to apoptosis may hold the key to development of new treatment initiatives. Much has already been learnt about the apoptotic pathways in cancer cells and proteins regulating these pathways. In most cells, apoptosis is dependent on the mitochondrial dependent pathway. This pathway is regulated by pro- and anti-apoptotic members of the Bcl-2 family, and manipulation of these proteins offers scope for a number of treatment initiatives. Effector caspases activated by the mitochondrial pathway or from death receptor signaling are under the control of the inhibitor of apoptosis protein (IAP) family. Certain proteins from mitochondrial can, however, competitively inhibit their binding to effector caspases. Information about the structure of these proteins has led to initiatives to develop therapeutic agents to block the IAP family. In addition to development of selective agents based on these two (Bcl-2 and IAP) protein families, much has been learnt about signal pathways that may regulate their activity. These in turn might provide additional approaches based on selective regulators of the signal pathways. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:9 / 18
页数:10
相关论文
共 125 条
[1]  
Aghajanian C, 2002, CLIN CANCER RES, V8, P2505
[2]   Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity [J].
Ali, IU ;
Schriml, LM ;
Dean, M .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (22) :1922-1932
[3]   Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ [J].
Arnt, CR ;
Chiorean, MV ;
Heldebrant, MV ;
Gores, GJ ;
Kaufmann, SH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (46) :44236-44243
[4]   Targeting death and decoy receptors of the tumour-necrosis factor superfamily [J].
Ashkenazi, A .
NATURE REVIEWS CANCER, 2002, 2 (06) :420-430
[5]   Rocaglamide derivatives are potent inhibitors of NF-κB activation in T-cells [J].
Baumann, B ;
Bohnenstengel, F ;
Siegmund, D ;
Wajant, H ;
Weber, C ;
Herr, I ;
Debatin, KM ;
Proksch, P ;
Wirth, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (47) :44791-44800
[6]   Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia [J].
Bellosillo, B ;
Villamor, N ;
López-Guillermo, A ;
Marcé, S ;
Bosch, F ;
Campo, E ;
Montserrat, E ;
Colomer, D .
BLOOD, 2002, 100 (05) :1810-1816
[7]  
Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO
[8]  
2-0
[9]  
Brown JM, 1999, CANCER RES, V59, P1391
[10]   Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor [J].
Brunet, A ;
Bonni, A ;
Zigmond, MJ ;
Lin, MZ ;
Juo, P ;
Hu, LS ;
Anderson, MJ ;
Arden, KC ;
Blenis, J ;
Greenberg, ME .
CELL, 1999, 96 (06) :857-868